Posted by Michael Wonder on 14 Jul 2022
FDA clears DyAnsys neurostimulation device first relief to treat diabetic neuropathic pain
14 July 2022 - First Relief, a PENS (percutaneous electrical neurostimulation) device, has been cleared by the US FDA for multiple treatments up to 56 days for symptomatic relief of chronic, intractable pain from diabetic peripheral neuropathy, Dyansys has announced.
The wearable device placed on the ear administers continuous pulses of a low-level electrical current over several days.
